Replies to post #197127 on Biotech Values

[alphahelix1]

Thx, I had somehow missed this.

[DewDiligence]

WVE +7% on PFE drug-discovery collaboration:

http://finance.yahoo.com/news/wave-life-sciences-enters-collaboration-110100062.html

[mcbio]

WVE IPOs 7.33M* shares @$16.00:

finance.yahoo.com/news/wave-life-sciences-announces-pricing-113000429.html

Looks like the underwriters held off on the start of trading due to the bearish biotech market today.

See #msg-118310217 and #msg-118331163 (S-1 excerpt) for background.

*Assuming exercise of underwriter’s option.

Just stumbled across this name for the first time tonight and was searching the board. Not a lot of recent chatter on this name. Per this recent PR, they claim their DMD Exon 51 drug has demonstrated 50-100% dystrophin restoration (compared to ~1% for Exondys and others) in in vitro studies: http://ir.wavelifesciences.com/phoenix.zhtml?c=254233&p=irol-newsArticle&ID=2221069 . As alluded to in some of the other posts from last year on the board, this seems to be an all-or-nothing, go big or go home, type of company. Not sure if there are specific reasons to believe their approach won't translate to the clinic or if there are otherwise IP issues with their approach (essentially developing stereopure versions of competitors' drugs as far as I can tell).